Insulin resistance is one of the main characteristics of polycystic ovary syndrome (PCOS) and is probably genetically predisposed. Possible associations of variable nucleotide tandem repeat (VNTR) polymorphism of the insulin gene (INS) with insulin resistance and PCOS in Slovene patients were investigated. A total of 117 PCOS patients and 108 age-matched female controls were genotyped for the INS VNTR polymorphism using real-time polymerase chain reaction and measurement of appropriate biochemical and clinical parameters. Serum fasting insulin (I 0 ) levels and the homeostasis model assessment index were significantly elevated in PCOS patients compared with controls. Class III INS VNTR alleles were significantly more frequent in the PCOS group. The interaction between body mass index and INS VNTR genotype was a significant predictor of serum I 0 level. The interaction of obesity and the III/III INS VNTR genotype might be a risk factor for the development of PCOS.
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy found in women of reproductive age. Its clinical picture is extremely heterogeneous and complex, with anovulation, hyperandrogenism and metabolic abnormalities (namely, insulin resistance, compensatory hyperinsulinaemia, abdominal obesity) as its main characteristics. 1 Insulin resistance, defined as decreased insulin-mediated glucose utilization, is found in 50 -90% of women with PCOS 2 ; its prevalence in the general population is, however, only 10 -25%. Disturbances in insulin secretion and action in PCOS patients have been found to sustain ovarian and adrenal androgen hypersecretion, 3 to suppress serum sex hormone-binding globulin (SHBG) levels and to affect hypothalamic control of gonadotropin secretion and appetite. 4 PCOS is responsible for a seven-fold increase in the risk of type 2 diabetes mellitus. 5 Moreover, PCOS patients share many metabolic abnormalities with type 2 diabetic patients. 2 PCOS is considered to be a multifactorial disorder with an obvious genetic background (oligogenic model). Genetic variants in the gene encoding insulin (INS gene; 11p15.5) have P Ferk, MP Perme, K Geršak Insulin gene polymorphism been proposed to be involved in the development of the metabolic features of PCOS. 5, 6 A minisatellite variable nucleotide tandem repeat (VNTR) polymorphism in the promoter of the INS gene (INS VNTR) 596 base pairs (bp) upstream of the translation initiation site was shown to influence transcriptional activity of the gene in vitro. 7, 8 In Caucasians, 11 variants of tandem repeats, 14 -15 bp in length, have been described. According to the minisatellite length, three discrete allele classes were distinguished: class I alleles (26 -63 repeats; approximate frequency 30%), class II alleles (extremely rare) and class III alleles (138 -209 repeats; approximate frequency 70%). Longer INS alleles were found to have higher transcriptional activity in vitro than shorter alleles. 7, 8 It has also been suggested that the polymorphism may influence INS gene transcription in vivo, 9 thus predisposing a person to develop insulin resistance and compensatory hyperinsulinaemia. Homozygous class I genotypes were associated with an increased risk of type 1 diabetes mellitus, 10 while class III alleles were proposed to be associated with an increased risk of type 2 diabetes mellitus, 5 obesity, 11 larger birth weight 12 and PCOS. 5, 6 Waterworth et al. 5 obtained positive evidence for the linkage of the PCOS/male pattern baldness phenotype (in 17 families) to the INS VNTR locus. Subsequently, a possible influence of the polymorphism on PCOS development was reported in an association study involving Spanish women with PCOS. 6 However, in other studies, linkage 13 and associations between the polymorphism and PCOS 14 -16 were not confirmed. Such contradictory results mean that the role of the polymorphism in the pathogenesis of PCOS remains questionable and requires further investigation.
The aim of the present study was to investigate a possible association between the INS VNTR polymorphism and the presence of PCOS, and to define factors that significantly influence serum fasting insulin (I 0 ) levels in Slovene PCOS patients. 19 Hyperandrogenism was assessed by the presence of hirsutism (Ferriman-Gallwey index score ≥ 8) 20 and/or by serum freetestosterone (FT) levels (which were calculated from serum total testosterone [TT] and SHBG levels), 21 by serum sulphated dehydroepiandrosterone (DHEA-S) levels, and by serum androstenedione (SA) levels. Other possible causes of hyperandrogenism (namely, late-onset congenital adrenal hyperplasia, Cushing's syndrome, androgensecreting tumours) had been previously excluded by endocrinologists.
Patients and methods

PATIENTS
The control group consisted of agematched healthy volunteers with proven fertility (seen in the clinic for normal pregnancy) and no menstrual cycle irregularities, no clinical or biochemical hyperandrogenism and no PCO. They also P Ferk, MP Perme, K Geršak Insulin gene polymorphism had no history of endocrinological or autoimmune disorders and had not undergone surgery to the pelvic region. All women were of European (Slovene) origin and were not genetically related.
The study protocol was approved by the National Medical Ethics Committee of the Republic of Slovenia (No. 97/05/01). Informed written consent was obtained from all women enrolled in the study.
BIOCHEMICAL AND CLINICAL PARAMETERS
Serum samples were obtained in the early follicular phase of the menstrual cycle, or randomly in amenorrhoeic patients. Serum luteinizing hormone (LH), follicle stimulating hormone (FSH), SHBG, TT, DHEA-S, SA, I 0 and fasting glucose (G 0 ) levels were measured. Serum LH, FSH and SHBG concentrations were determined by chemiluminescent immunometric assay using LH-Immulite ® , FSH-Immulite ® and SHBG-Immulite ® , respectively (Diagnostic Products Corporation, Los Angeles, CA, USA). Serum TT, DHEA-S and SA levels were measured using commercial radioimmunoassay kits (TT: DiaSorin, Saluggia, Italy; DHEA-S: ICN Biomedicals, Costa Mesa, CA, USA; SA: Diagnostic Systems Laboratories, Webster, TX, USA). For determination of serum I 0 levels, an immunoradiometric assay kit was used (DiaSorin), while serum G 0 levels were determined by the glucose oxidase method using a Beckman Glucose Analyser II (Beckman Coulter, Fullerton, CA, USA). The intra-and inter-assay coefficients of variation were between 1.6% and 13.0%.
Body mass index (BMI) was calculated as mass (kg) divided by height (m 2 ). Insulin resistance was assessed by the ratio of I 0 /G 0 and by the homeostasis model assessment (HOMA) index, calculated as [I 0 (µU/ml) × G 0 (mmol/l)]/22.5.
GENOTYPE ANALYSIS
For all women included in the study, genomic DNA was isolated from peripheral blood leucocytes using the commercial FlexiGene ® kit (Qiagen, Hilden, Germany), following protocols recommended by the manufacturer.
Genotyping of the INS VNTR was performed indirectly by analysing its surrogate marker, the -23 A to T (HphI) polymorphism of the INS gene. In Europeans, the -23 T alleles have been found to be in complete linkage disequilibrium with INS VNTR class I alleles and the -23 A alleles have been found to be in complete linkage disequilibrium with INS VNTR class III alleles. 22 Real-time polymerase chain reaction (PCR) technology was applied using an appropriate single nucleotide polymorphism (SNP) genotyping assay (TaqMan ® SNP Genotyping Assay; Applied Biosystems, Werterstadt, Germany). All PCR reactions were performed on a sequence detection system (ABI Prism TM 7000, version 1.1; Applied Biosystems) on 96-well optical plates. Each reaction mixture had a final volume of 25 µl and consisted of: 12.5 µl 2 × TaqMan ® Universal PCR Master Mix/No AmpErase ® UNG (Applied Biosystems) (1 × final concentration); 0.625 µl 40 × TaqMan ® SNP Genotyping Assay (1 × final concentration); and 70 ng genomic DNA diluted in bi-distilled water. The TaqMan ® SNP Genotyping Assay contained unlabelled target-specific primers and 5´fluorescentlabelled probes with the following sequences: forward primer 5′-GGG CAC CTG GCC TTC AG-3′; reverse primer 5′-CCA TGG CAG AAG GAC AGT GA-3′; TaqMan ® MGB VIC dyelabelled probe for detection of HphI T alleles 5′-CCT GCC TGT CTC CCA GA-3′; and TaqMan ® MGB 6-FAM™ dye-labelled probe for detection of HphI A alleles 5′-CTG CCT GTC ACC CAG A-3′. Thermal cycling Insulin gene polymorphism conditions included an initial denaturation step of 10 min at 95 ºC, followed by 40 cycles of 15 s denaturation at 92 ºC and 1 min annealing/extension steps at 60 ºC (TaqMan ® Universal PCR protocol; Applied Biosystems). In each run, T/T, A/A and A/T control genotypes (all of them in duplicate) as well as four no-template controls were used. Finally, data evaluation was undertaken using the allelic discrimination post-reading option on the ABI Prism Sequence Detection Software (Applied Biosystems).
STATISTICAL ANALYSIS
The χ 2 test was used to compare the INS VNTR allele and genotype frequencies between study and control groups. Student's t-test was used to compare mean values of age, BMI, serum LH, FSH, TT, FT, DHEA-S, SA, I 0 , G 0 , SHBG levels, I 0 /G 0 ratio and HOMA index between both patient groups. Linear regression analyses were performed, with serum I 0 levels as a dependent variable. All statistical tests were undertaken using SPSS ® (version 13.0; SPSS Inc., Chicago, IL, USA) for Windows ® . P-values < 0.05 were considered to be statistically significant.
Results
A total of 117 patients fulfilling the criteria for PCOS 17,18 were enrolled in the study group. The control group consisted of 108 age-matched women.
BIOCHEMICAL AND CLINICAL PROFILES
The PCOS and control group members differed in their biochemical profiles (Table  1 ). In PCOS patients, mean BMI, serum LH, TT, FT, SA and I 0 levels as well as I 0 /G 0 ratio and HOMA index were significantly elevated (P < 0.001), while serum SHBG levels were significantly lower (P < 0.001), compared with control patients. There were no significant differences between the PCOS and All the control group women were lean (18 kg/m 2 ≤ BMI ≤ 25 kg/m 2 ), whereas 13% of the PCOS patients were overweight (BMI > 25 kg/m 2 ; all other PCOS patients were lean). According to the normal range of serum I 0 levels in the laboratory, all controls were normoinsulinaemic (serum I 0 5 -25 mU/l) and only two (1.7%) PCOS patients were hyperinsulinaemic (serum I 0 > 25 mU/l).
PCOS
INS VNTR GENOTYPING
The INS VNTR allele frequencies in PCOS patients and controls were 79.2% versus 70.4% for the class III alleles and 20.8% versus 29.6% for the class I alleles, respectively; the frequencies were significantly different between the two groups of patients (P = 0.03). Conversely, the overall genotype distributions between study and control groups did not differ significantly, although an excess of III/III genotype was evident in PCOS patients (Fig. 1 ).
PREDICTING SERUM FASTING INSULIN LEVELS IN PCOS PATIENTS
Linear regression analysis was performed, with serum I 0 levels in PCOS patients as a dependent variable and INS genotype as an independent variable. Since the INS genotype is a categorical variable with three levels, appropriate dummy variables were created, with the III/III genotype as a reference group. The independent variable was not found to be significant for predicting serum I 0 levels in PCOS patients.
Because of the possibility of a confounding effect of BMI and serum TT levels when studying the effect of INS genotype on serum I 0 levels in PCOS patients, a multivariable linear regression model was fitted (serum I 0 levels as a dependent variable; BMI, serum TT levels, INS genotype and BMI-INS genotype interaction as predictors). The results of the model were as follows: BMI, serum TT levels and the interaction all proved to be significant predictors of serum I 0 levels (P < 0.001, P = 0.011 and P < 0.001, respectively). To understand better the effect of the interaction (based on the model), the predicted differences in serum I 0 levels between various INS genotypes at two different BMI values were calculated ( Table  2 ). The model as a whole explained the considerable amount of variation in serum I 0 levels (adjusted r 2 = 0.40). However, it is noteworthy that BMI as the only predictor explains most of this variation (adjusted r 2 = 0.28).
Discussion
The present study was undertaken to investigate a possible association of the INS Focusing on significantly higher serum I 0 levels and insulin resistance observed in the study group (significantly elevated I 0 /G 0 ratio and HOMA index compared with controls), we suggest that the PCOS patients exhibited an early stage of insulin metabolic abnormalities; however, hyperinsulinaemia was observed in only 1.7% of these patients. Serum G 0 levels were in the normal range in all PCOS women and controls, reflecting efficient glycaemic control in both groups.
We further suggest that a proportion of PCOS patients with serum I 0 levels in the upper-normal range might have a genetic predisposition for future development of hyperinsulinaemia. This suggestion is mainly based on the fact that the PCOS patients were predominantly earlydiagnosed young girls and that all of them were anovulatory; it was previously observed that anovulatory women tend to be hyperinsulinaemic. 5 This speculation, if confirmed in further studies, might have useful clinical implications, especially from the pharmacogenomic aspect; therapies with drugs that improve insulin action could be targeted and individually tailored according to the patient's genetic predisposition and the PCOS clinical picture. It would be interesting to follow the changes in insulin action and the success of the treatments in those patients over time.
Furthermore, molecular genetic analysis in the present study revealed a significant excess of INS VNTR class III alleles in PCOS patients compared with controls, with evidently higher frequencies of III/III genotypes in women with PCOS. These results are consistent with previously described associations between the III/III genotype and increased risk of PCOS, 5, 6 although contradictory observations have been made by others. 13 -16 Accordingly, the exact role of the polymorphism in the pathogenesis of PCOS remains unclear and should be further investigated.
The length of the INS VNTR alleles is probably not the only factor to influence transcriptional activity of the INS gene; sequence heterogeneity of the tandem repeats and consequent complex interactions between different genetic factors could also contribute to the gene's overall transcriptional activity. 7 In addition, precise inclusion criteria for the participation of PCOS patients in a study (as used in the present study) are also of great importance, particularly as different PCOS subgroups might have different genetic predispositions An important finding of the present study was that the influence of the INS genotype on serum I 0 levels in PCOS patients is affected by BMI; the INS genotype had no effect on serum I 0 levels in PCOS patients who were not over-weight, while the influence became significant in PCOS patients with higher BMI values. In this respect, the III/III genotype was found to affect the insulin biochemical picture only in overweight PCOS patients. It could be speculated that maintaining BMI in the normal range could overcome the susceptibility genotype.
It is noteworthy that BMI was the most significant predictor for serum I 0 levels in PCOS patients; nearly one-third of the variability in serum I 0 levels could be explained by BMI as the only predictive factor. Since PCOS women with higher BMI values were found to have higher serum I 0 levels compared with PCOS women with BMI values in the normal range, it is speculated that obesity could contribute to susceptibility to hyperinsulinaemia in PCOS. However, the relatively small number of patients included in the study might have resulted in a type 2 statistical error, especially when considering that PCOS is a complex disease with multifactorial pathogenesis.
In conclusion, the INS VNTR polymorphism might be a risk factor for PCOS development, especially in combination with obesity. However, the precise role of the polymorphism in the pathogenesis of PCOS remains to be elucidated in further large and carefully designed population studies.
